Business Recorder3m
FTSE 100 opens higher on GSK boost
The UK’s benchmark FTSE 100 opened higher on Thursday, led by gains in GSK following the settlement of lawsuits ...
GSK shares leap after drug firm settles US Zantac cancer claim lawsuit
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
Citi Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
GSK Shares Gain Over 5% At LSE After Reaching $2.2 Billion Settlement Over Heartburn Medicine Zantac
In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...